 |
Pharmacyclics Reports First Quarter 2013 Results
May 1, 2013
|
41.0 KB |
|
| |
SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its three months ended March 31, 2013.
Financial Results for the Three Months Ended March 31, 2013
Non-GAAP net loss reported for the quarter ended March 31, 2013 was $28.3 mil...
|
|
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Apr 24, 2013
|
8.4 KB |
|
| |
SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three months ended March 31, 2013 after the NASDAQ Market closes on Wednesday, May 1, 2013. The Company will conduct a conference call and audio webcast at 4:30 p...
|
|
Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
Apr 18, 2013
|
13.8 KB |
|
| |
SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), (RESONATE™) was achie...
|
|
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Apr 11, 2013
|
13.2 KB |
|
| |
SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE™-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patie...
|
|
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Apr 8, 2013
|
13.3 KB |
|
| |
SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of chara...
|
|
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Apr 8, 2013
|
12.8 KB |
|
| |
SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymph...
|
|
Pharmacyclics, Inc. Prices Public Offering of Common Stock
Mar 8, 2013
|
8.3 KB |
|
| |
SUNNYVALE, Calif., March 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, today announced the pricing of a previously announced underwritten registered public offer...
|
|
Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Mar 7, 2013
|
9.1 KB |
|
| |
SUNNYVALE, Calif., March 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, today announced that it has commenced an underwritten registered public offering of 2,200,...
|
|
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Feb 14, 2013
|
33.1 KB |
|
| |
SUNNYVALE, Calif., Feb. 14, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its six and three months ended December 31, 2012. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the...
|
|
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Feb 12, 2013
|
15.5 KB |
|
| |
SUNNYVALE, Calif., Feb. 12, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the investigational oral agent ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and...
|
|
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Feb 7, 2013
|
8.5 KB |
|
| |
SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended December 31, 2012 after the NASDAQ Market closes on Thursday, February 14, 2013. The Company will conduct a conference call and audio we...
|
|
Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Hematology (ASH) Annual Meeting
Dec 11, 2012
|
23.0 KB |
|
| |
ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) and its collaborators provided clinical and pre-clinical presentations on ibrutinib and ibrutinib combinations at the 2012 ASH Annual Meeting. Ibrutinib inhibits Bruton's tyrosine kinase (BTK), which is known to be expressed in chronic lymphocytic leukemia (CLL), small lymphoc...
|
|
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Dec 11, 2012
|
15.0 KB |
|
| |
ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study suggesting that in patients with relapsed or refractory mantle cell lymphoma (MCL), both those who were bortezomib-naive and bortezomib-exposed, the investigational oral agent ibrutini...
|
|
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Dec 8, 2012
|
17.4 KB |
|
| |
ATLANTA, Dec. 8, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up results that its investigational oral therapy ibrutinib (PCI-32765), as a single agent, resulted in durable responses for patients over 65 years of age with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and for...
|
|
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
Nov 5, 2012
|
33.3 KB |
|
| |
SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal 2013 first quarter ended September 30, 2012.
Financial Results for First Quarter Ended September 30, 2012
The GAAP (Generally Accepted Accounting Principles) net in...
|
|
Pharmacyclics® Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial
Oct 15, 2012
|
12.8 KB |
|
| |
SUNNYVALE, Calif., Oct. 15, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the international, randomized Phase III clinical trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) ha...
|
|
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
Sep 5, 2012
|
37.0 KB |
|
| |
SUNNYVALE, Calif., Sept. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal year and fourth quarter ended June 30, 2012.
Financial Results for Fiscal Year and Fourth Quarter Ended June 30, 2012
The non-GAAP (Generally Accepted Accounting Principles) net in...
|
|
Pharmacyclics® Triggers Significant Milestone Payment For Mantle Cell Lymphoma Clinical Trial
Aug 20, 2012
|
11.7 KB |
|
| |
SUNNYVALE, Calif., Aug. 20, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the clinical trial, SPARK (MCL2001), of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a second $50 million milestone pa...
|
|
Pharmacyclics® Appoints Joshua T. Brumm Executive Vice President of Finance
Aug 14, 2012
|
8.7 KB |
|
| |
SUNNYVALE, Calif., Aug. 14, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointment of Joshua T. Brumm as its Executive Vice President of Finance. Mr. Brumm will have global responsibility for corporate finance, accounting, investor relations and IT.
Bob Duggan, CEO of Pharmacyclics stated, "We are very please...
|
|
/C O R R E C T I O N -- Pharmacyclics, Inc./
Aug 1, 2012
|
15.4 KB |
|
| |
In the news release, Pharmacyclics® Triggers Significant Milestone Payment and Provides Clinical Program Update, issued 01-Aug-2012 by Pharmacyclics, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "calendar 2012" rather than "calendar 2013" as originally issued inadvertently. The compl...
|
|
|
